XML 72 R4.htm IDEA: XBRL DOCUMENT v2.4.0.8
Consolidated Statements Of Operations (USD $)
In Thousands, except Per Share data, unless otherwise specified
 12 Months Ended 275 Months Ended
Dec. 31, 2013
Dec. 31, 2012
Dec. 31, 2011
Dec. 31, 2013
Revenue   $ 35 $ 50 $ 3,166
Operating expenses:        
Research and development 109,719 101,522 99,959 1,577,292
General and administrative 59,682 45,473 40,630 485,386
In-process research and development costs       19,726
Goodwill impairment       151,428
Total operating expenses 169,401 146,995 140,589 2,233,832
Loss from operations (169,401) (146,960) (140,539) (2,230,666)
Other income (expense) (635) (1,191) 1,541 (2,902)
Interest expense on note payable to principal stockholder (6,309) (10,491) (10,883) (45,134)
Interest expense on notes (15,153) (11,139) (10,941) (55,086)
Interest income 8 7 18 37,004
Loss before benefit for income taxes (191,490) (169,774) (160,804) (2,296,784)
Income tax benefit   408   382
Net loss (191,490) (169,366) (160,804) (2,296,402)
Deemed dividend related to beneficial conversion feature of convertible preferred stock       (22,260)
Accretion on redeemable preferred stock       (952)
Net loss applicable to common stockholders $ (191,490) $ (169,366) $ (160,804) $ (2,319,614)
Net loss per share applicable to common stockholders - basic and diluted $ (0.64) $ (0.94) $ (1.32)  
Shares used to compute basic and diluted net loss per share applicable to common stockholders 299,591 180,855 121,817